ArticleACS applied bio materials2025
Enhanced Intracellular IR780 Delivery by Acidity-Triggered PEG-Detachable Hybrid Nanoparticles to Augment Photodynamic and Photothermal Combination Therapy for Melanoma Treatment.
Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Overcoming Biophysical Barriers in Melanoma Photomedicine: From Photodynamic Therapy to Smart Nanodelivery and Photoimmunotherapy.International journal of molecular sciences · 2026Review
- Naringenin Nanocrystals Containing PluronicGels (Basel, Switzerland) · 2026Article
- ZIF-8 Nanodrug Delivery Systems: Construction Strategies, Functional Modifications, and Advances in Synergistic Tumor Therapy.International journal of nanomedicine · 2026Review
- Synergistic photothermal therapy of esophageal cancer using Pt@MOF@PSs nanozymes.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PEGylation of drug-carrying nanoparticles has often been used to prolong blood circulation and improve drug deposition at tumor sites. Nevertheless, the PEG-rich hydrophilic surfaces retard the release of the payloads and internalization of therapeutic nanoparticles by cancer cells, thus lowering the anticancer efficacy. To boost the anticancer potency of the combined photodynamic therapy (PDT) and photothermal therapy (PTT) against melanoma by conquering the PEG dilemma, herein, the hybrid PEGylated chitosan-covered polydopamine (PDA) nanoparticles (PCPNs) with acidity-elicited PEG detachment ability were fabricated as carriers of IR780, a small-molecule photosensitizer used for PTT and PDT. The IR780@PCPNs displayed a uniform, solid-like spherical shape and sound colloidal stability. Under near-infrared (NIR) irradiation, the IR780@PCPNs showed prominent photothermal conversion efficiency (ca. 54.6%), robust photothermal stability, reduced IR780 photobleaching, sufficient singlet oxygen (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.